Pregled bibliografske jedinice broj: 824418
Evaluation of the Specificity of a New HCV Antigen/Antibody Combination test
Evaluation of the Specificity of a New HCV Antigen/Antibody Combination test // Vox Sanguinis
Madrid, Španjolska, 2007. str. 131-131 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 824418 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Evaluation of the Specificity of a New HCV Antigen/Antibody Combination test
Autori
Mihaljević, Ivanka ; Lovrić, Manuela ; Berendika, Mirka ; Vockel, Angela
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Vox Sanguinis
/ - , 2007, 131-131
Skup
XVIIth Regional Congress of the ISBT
Mjesto i datum
Madrid, Španjolska, 23.06.2007. - 27.06.2007
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
HCV Ag/Ab test
Sažetak
Aims: This study was undertaken to evaluate the specificity of the Murex HCV Ag/Ab Combination assay, to compare to another antigen-antibody combination assay (Monolisa HCV Ag-Ab Ultra, Bio-Rad) or a combination of antibody assays with a separate HCV antigen assay. Methods: Murex HCV Ag/Ab Combination assay was used to test 1.022 presumed negative routine donor specimens. 584 specimens were tested in parallel by Monolisa HCV Ag-Ab Ultra and another 438 by Ortho HCV Core Ag test in combination with Ortho HCV Enhanced SAVe or Abbott PRISM anti-HCV tests. In addition, 357 repeatedly reactive (RR) by other HCV serological assays were analyzed to characterize sensitivity and false-reactivity rate for this new device. Results: 1.022 routine donor samples were tested by Murex assay, resulting in a specificity of 99, 80 % (2/1.022). 582 of these were also tested by Bio-Rad with similar specificity of 99, 82% (1/582). No false-reactive results were seen when separate HCV antigen and HCV antibody assays were used. In a group of 357 a-HCV RR donors, 9 RIBA-3 positive were clearly detected by all three assays (Murex, Bio-Rad and Ortho HCV Enhanced SAVe). Out of 88 RIBA-3 indetermined samples, 11 were found reactive by Murex, 32 by Bio-Rad and 23 by Ortho Enhanced HCV. In the group of 242 RIBA negative samples, 3 were Murex reactive, 47 tested positive by Bio-Rad and 14 were Ortho positive. Conclusion: The Murex HCV Ag/Ab combination assay has demonstrated excellent specificity and may thus be considered as less expensive alternative to the introduction of HCV RNA screening.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
Hrvatski zavod za transfuzijsku medicinu
Profili:
Ivanka Mihaljević
(autor)